Related Experiment Video
Updated: Jul 4, 2025

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
Insulin sensitivity and beta cell function after duodenal mucosal resurfacing: an open-label, mechanistic, pilot
Celine B E Busch1, Suzanne Meiring1, Annieke C G van Baar1
1Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, location AMC, Amsterdam, the Netherlands.
Duodenal mucosal resurfacing (DMR) improved insulin sensitivity and beta cell function in type 2 diabetes patients. This endoscopic therapy targets the duodenum, enhancing glucose control without altering incretin levels.
Area of Science:
- Endocrinology
- Gastroenterology
- Metabolic Diseases
Background:
- The duodenum plays a crucial role in glucose homeostasis.
- Duodenal mucosal resurfacing (DMR) is an endoscopic procedure for type 2 diabetes (T2D) that ablates duodenal mucosa.
- DMR improves glycemic control, but mechanisms are unclear.
Purpose of the Study:
- To investigate changes in glucoregulatory hormones after DMR.
- To assess alterations in insulin sensitivity and beta cell function post-DMR.
Main Methods:
- 28 T2D patients on non-insulin medications underwent DMR.
- Mixed meal tests (MMT) were conducted at baseline and 3 months.
- Measured plasma glucose, insulin, C-peptide, GLP-1, GIP, and calculated insulin sensitivity and beta cell function indices.
Main Results:
- Significant improvements in insulin sensitivity (HOMA-IR, Matsuda index, hepatic insulin resistance) and beta cell function (disposition index, insulin secretion rate) were observed.
- Fasting insulin, glucagon, and C-peptide levels decreased significantly.
- Postprandial glucose and glucagon declined; GLP-1 and GIP levels remained unchanged.
Conclusions:
- DMR enhances insulin sensitivity and secretion in T2D patients within 3 months.
- Incretin hormones are unlikely to mediate the glucose-lowering effects of DMR.
- These findings support the duodenum as a therapeutic target for T2D management.
More Related Videos
12:32High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
10:09Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
Published on: May 11, 2015
Related Concept Videos
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Insulin Secretory Vesicles
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...